Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to make sure Talquetamab is safe to use and figure out how much of it people should take. They will test it at different levels to see what works best and make sure it doesn't hurt anyone. Then they will test it more to make sure the recommended amount is still safe.
This study wants to make sure Talquetamab is safe to use and figure out how much of it people should take. They will test it at different levels to see what works best and make sure it doesn't hurt anyone. Then they will test it more to make sure the recommended amount is still safe.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 [Dose Expansion]).
The purpose of this study is to characterize the safety of Talquetamab and to determine the recommended Phase 2 dose(s) (RP2Ds) and dosing schedule assessed to be safe for Talquetamab (Part 1 [Dose Escalation]) and to further characterize the safety of Talquetamab at the recommended Phase 2 dose(s) (RP2Ds) (Part 2 [Dose Expansion]).
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: